Volume 93, Issue S255
ABS15-0532
Free Access

Altered micro-RNA21 expression correlates with enhanced peripheral IL-23p19 levels patients with primary Sjögren's syndrome

J. Ni Gabhann

J. Ni Gabhann

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

Search for more papers by this author
Q. Pilson

Q. Pilson

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

Search for more papers by this author
C. Jefferies

C. Jefferies

Molecular and Cellular Therapeutics, Royal College of Surgeons in Ireland, Dublin, Ireland

Search for more papers by this author
C. Murphy

C. Murphy

Department of Ophthalmology- Royal Victoria Eye and Ear Hospital, Royal College of Surgeons in Ireland, Dublin, Ireland

Search for more papers by this author
First published: 23 September 2015

Abstract

Purpose

Sjögren's syndrome (SS) is a systemic autoimmune disorder characterized by inflammation that affects mucous membranes particularly those of the exocrine glands, causing dry eyes and dry mouth. Previous investigations have suggested that dysregulated systemic inflammation contributes to the development and pathogenesis of SS. This study aimed to investigate potential mechanisms responsible for over production of pathogenic cytokines in SS patients.

Methods

Peripheral blood mononuclear cells and serum were prepared from whole blood taken from both healthy controls and pSSpatients. Gene induction and micro-RNA expression were analysed by real-time PCR. Cytokine levels were determined by ELISA.

Results

We observed significantly enhanced expression of the pro-inflammatory micro-RNA, miR-155 (p ≤ 0.05) and significantly reduced levels of the IL-10 promoting miR, miRNA-21 (p ≤ 0.05) compared to healthy controls. In keeping with this altered pattern of miR expression we observed significantly increased serum levels of pro-inflammatory cytokines (IL-6, IL-8 and TNF-a) as well as the Th17 promoting cytokine, IL-23p19 (p ≤ 0.05). Altered expression of previously identified targets of miR-155 (SHIP-1, SOCS1 – potent anti-inflammatory regulators) and miR-21 (IL12p35 and PDCD4, positive regulators of inflammation) was also observed. Significantly a moderate negative correlation (r = −0.657, p ≤ 0.05) was observed between reduced miR-21 expression and increased peripheral IL-23p19 levels in pSS patients, suggesting a link between altered miR expression and disease pathogenesis.

Conclusions

Our data suggest that abnormal expression or regulation of miRs and consequently miR regulated genes in innate immunity may contribute to the initiation and progression of SS via overproduction of pathogenic cytokines.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.